Polyomavirus-specific T cells - ViraCyte

Drug Profile

Polyomavirus-specific T cells - ViraCyte

Alternative Names: BKV-specific T cell therapy - ViraCyte; BKV-specific T cells - ViraCyte; HLA-matched BKV-specific T cells - ViraCyte; HLA-matched Viralym-B cells; Human leukocyte antigen (HLA)-matched BK virus-specific T lymphocytes - ViraCyte; Polyomavirus-specific T cell therapy - ViraCyte; Viralym-B

Latest Information Update: 07 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ViraCyte
  • Class T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Human polyomavirus infections

Most Recent Events

  • 05 Jul 2017 ViraCyte receives SBIR grant from National Heart, Lung and Blood Institute for T cell immunotherapy development in Polyomavirus infections
  • 08 Dec 2014 Preclinical trials in Human polyomavirus infections in USA (IV)
  • 08 Dec 2014 ViraCyte plans a phase I trial for Human polyomavirus infections in USA (NCT02313844)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top